Low molecular weight heparin treatment and impact of inherited thrombophilia type in pregnancies with previous adverse outcome

References

• Bremme K. Haemostatic changes in pregnancy. Res Clin Haematol 2003;16:153–68
   PubMed Web of Science ®Google Scholar
• Paidas MJ, Ku DH, Langhoff-Roos J, Arkel YS. Inherited thrombophilias and adverse pregnancy outcome: screening and management. Semin Perinatol 2005;29:150–63
   PubMed Web of Science ®Google Scholar
• Brenner B. Thrombophilia and pregnancy complications. Pathophys Haemost Thromb 2006;35:28–35
   PubMedGoogle Scholar
• Pabinger I, Vormittag R. Thrombophilia and pregnancy outcomes. J Thromb Hemost 2005;3:28–35
   Web of Science ®Google Scholar
• Sarig G, Vidergor G, Brenner B. Assessment and management of high-risk pregnancies in women with thrombophilia. Blood Rev 2009;23:143–7
   PubMed Web of Science ®Google Scholar
• Ayala RG, Papadakis E, Brenner B. Combined thrombophilia and obstetric complications. Open Atherosc and Thromb J 2009;2:38–41
   Google Scholar
• Yang C, Fangfang W, Jie L, et al. Angiotensin-converting enzyme insertion/deletion (I/D) polymorphisms and recurrent pregnancy loss: a meta analysis. J Assist Reprod Genet 2012;29:1167–73
   PubMed Web of Science ®Google Scholar
• Nakamura E, Okamoto T, Nagaya K, Hayashi T. Maternal deletion allele of angiotensin-converting enzyme gene is associated with fetal growth restriction. Pediatr Dev Pathol 2012;15:114–17
   PubMed Web of Science ®Google Scholar
• Said JM, Tsui R, Borg AJ, et al. The PAI-1 4G/5G polymorphism is not associated with an increased risk of adverse pregnancy outcome in asymptomatic nulliparous women. J Thromb Haemost 2012;10:881–6
   PubMed Web of Science ®Google Scholar
• Mello G, Paretti E, Fatini C, et al. Low molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension 2005;45:86–91
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Marozio L, Frusca T, et al. Maternal thrombophilia and the risk of recurrence of preeclampsia. Am J Obstet Gynecol 2009;200:46.e1–e5
   Web of Science ®Google Scholar
• Grandone E, De Stefano V, Rossi E, et al. Antithrombotic prophylaxis during pregnancy in women with deficiency of natural anticoagulants. Blood Coagul Fibrinolysis 2008;19:226–30
   PubMed Web of Science ®Google Scholar
• Kupferminc MJ, Rimon E, Many A, et al. Low molecular weight heparin treatment during subsequent pregnancies of women with inherited thrombophilia and previous severe pregnancy complications. J Matern Fetal Neonatal Med 2011;24:1042–5
   PubMed Web of Science ®Google Scholar
• Rey E, Garneau P, David M, et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost 2009;7:58–64
   PubMed Web of Science ®Google Scholar
• Martinelli I, Ruggenenti P, Cetin I, et al. Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood 2012;119:3269–75
   PubMed Web of Science ®Google Scholar
• Galambosi PJ, Kaaja RJ, Stefanovic V, Ulander VM. Safety of low-molecular weight heparin during pregnancy: a retrospective controlled cohort study. Eur J Obstet Gynecol Reprod Med 2012;163:154–9
   PubMed Web of Science ®Google Scholar
• Roje D, Tadin I, Marušić J, et al. Porodne težine i duljine novorođenčadi u Splitu, opravdanost razvijanja vlastitih referentnih vrijednosti za ocjenjivanje fetalnog rasta. Gynecol Perinatol 2005;14:66–74
   Google Scholar
• Sobel ML, Kingdom J, Drewlo S. Angiogenic response of placental vili to heparin. Obstet Gynecol 2011;117:1375–83
   PubMed Web of Science ®Google Scholar
• De Carolis S, Ferrazzani S, De Stefano V, et al. Inherited thrombophilia: treatment during pregnancy. Fetal Diagn Ther 2006;21:281–6
   PubMed Web of Science ®Google Scholar
• Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost 2002;20:35–44
   Google Scholar
• Grandone E, Brancaccio V, Colaizzo D, et al. Preventing adverse obstetric outcomes in women with genetic thrombophilia. Fertil Steril 2002;78:371–5
   PubMed Web of Science ®Google Scholar
• Gris JC, Mercier E, Quere I, et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004;103:3695–9
   PubMed Web of Science ®Google Scholar
• Brenner B, Hoffman R, Carp H, et al.; for the LIVE-ENOX Investigators. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J Thromb Haemost 2005;3:227–9
   PubMed Web of Science ®Google Scholar
• Leduc L, Dubois E, Takser L, et al. Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. J Obstet Gynecol Can 2007;29:787–93
   PubMedGoogle Scholar
• de Vries JIP, van Pampus MG, Hague WM, et al.; on behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. J Thromb Haemost 2012;10:64–72
   PubMed Web of Science ®Google Scholar
• Fawzy M, Shokeir T, El-Tatongy M, et al. Treatment options and pregnancy outcome in women with idiopathic recurrent miscarriage: a randomized placebo-controlled study. Arch Gynecol Obstet 2008;278:33–8
   PubMed Web of Science ®Google Scholar
• Kaandorp SP, Goddijn M. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010;362:1586–96
   PubMed Web of Science ®Google Scholar
• Ferrazzi E. The evidence of the HAPPY trial is severely limited by the criteria and the methodology of recruitment. Available from: http://bloodjournal.hematologylibrary.org/content/119/14/3269.long/reply#bloodjournal_el_6943 [last accessed 1 May 2014]
   Google Scholar